# ENTPD5 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- ENTPD5 is an endoplasmic reticulum (ER) luminal UDPase critical for protein N-glycosylation fidelity and the unfolded protein response (UPR), functioning by hydrolyzing UDP to UMP and Pi, thereby influencing glycoprotein folding and cellular energetics.
- The gene exhibits significant alternative splicing, generating isoforms (e.g., v1, v2, v3) with distinct ER retention properties and functional implications, where high expression of the v3 isoform is associated with poor prognosis in ovarian and lung cancers.
- ENTPD5 is implicated in multiple malignancies, including prostate, ovarian, lung, and colorectal cancers, often through gene amplification or overexpression, and its activity links protein glycosylation to the pentose phosphate pathway (PPP), supporting cancer cell proliferation and metabolic reprogramming.
- Somatic mutations in ENTPD5, though less frequent than expression alterations, are observed in ~2-5% of cancers, particularly colorectal and prostate, often affecting conserved apyrase conserved regions (ACRs) and predicted to impair catalytic activity.
- ENTPD5 demonstrates synthetic lethality with PTEN deficiency, making it a potential therapeutic target in PTEN-null cancers like prostate cancer, with preclinical investigations exploring nucleotide analogs, polyoxometalates, and antisense oligonucleotides as inhibitors.
- Beyond cancer, ENTPD5 plays a role in skeletal mineralization (as shown in zebrafish) and hepatic homeostasis, with emerging evidence linking it to metabolic dysfunction-associated steatohepatitis (MASH) and potential modulation of immune regulation via purinergic signaling pathways.

---

## Executive Summary & Key Metadata

The *ENTPD5* gene encodes ectonucleoside triphosphate diphosphohydrolase 5 (also known as CD39L4, NTPDase5, or PCPH), a member of the E-NTPDase family that hydrolyzes nucleoside triphosphates and diphosphates. Unlike most family members, ENTPD5 is localized predominantly to the endoplasmic reticulum (ER) lumen, where it functions as a UDPase that regulates protein N-glycosylation fidelity, the unfolded protein response (UPR), and cellular energetics. Its dual identity as the PCPH proto-oncogene links it to both normal physiology and oncogenic transformation. ENTPD5 has been implicated in multiple malignancies, including prostate, ovarian, lung, and colorectal cancers, as well as in skeletal mineralization, hepatic homeostasis, and spermatogenesis. The gene's complex splicing landscape generates multiple isoforms with distinct functional and prognostic implications.

| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | ENTPD5 |
| **UniProt Accession** | O75356 |
| **Representative PDB ID** | True (homology models; experimental structures pending) |
| **Chromosomal Locus** | 14q24.2 |
| **Primary Molecular Function** | ER luminal UDPase; hydrolysis of nucleoside diphosphates (UDP, GDP) and triphosphates; regulation of N-glycoprotein folding |
| **Disease & Pathology Associations** | Prostate cancer, epithelial ovarian cancer, lung cancer, colorectal cancer, hepatocellular carcinoma, skeletal mineralization defects, spermatogenic arrest, metabolic dysfunction-associated steatohepatitis (MASH) |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The *ENTPD5* gene is located on the long arm of human chromosome 14 at cytogenetic band 14q24.2. The genomic span covers approximately 45 kilobases (kb) of DNA. The reference genome assembly (GRCh38/hg38) places *ENTPD5* between the coordinates chr14:73,950,000–73,995,000 (approximate; exact coordinates vary by assembly version). The gene is oriented on the minus strand relative to the centromere-to-telomere orientation of chromosome 14.

The gene comprises 13 exons and 12 introns, with the translation initiation codon located in exon 1 and the stop codon in exon 13. The canonical transcript (ENST00000216847.10) spans 2,214 nucleotides of coding sequence, producing a 430-amino-acid protein. The promoter region upstream of exon 1 lacks a canonical TATA box but contains multiple GC-rich elements, consistent with a housekeeping-like expression pattern modulated by tissue-specific transcription factors. Putative binding sites for SP1, E2F, and members of the AP-1 family have been identified in the proximal promoter region, suggesting responsiveness to proliferative and stress signals.

### 1.2 Promoter Architecture and Regulatory Elements

The 5' untranslated region (UTR) of *ENTPD5* is unusually long (~300 nucleotides) and contains multiple upstream open reading frames (uORFs) that may modulate translation efficiency under stress conditions. Chromatin immunoprecipitation sequencing (ChIP-seq) data from ENCODE reveal active enhancer marks (H3K27ac, H3K4me1) in intronic regions, particularly within introns 2 and 5, which may serve as tissue-specific enhancers. A CpG island spanning the promoter and exon 1 is subject to differential methylation in cancer cell lines, with hypomethylation correlating with increased expression in prostate and ovarian tumors [1].

Transcription factor binding sites identified by in silico promoter analysis include:

- **SP1**: Multiple GC-box motifs; regulates basal transcription
- **E2F1**: Cell cycle-dependent activation
- **c-MYC**: E-box elements (CACGTG) in the proximal promoter
- **p53**: Response elements in intron 1, relevant to mutant p53-driven upregulation [2]
- **HIF1A**: Hypoxia response elements in the distal promoter

### 1.3 Alternative Splicing and Isoform Diversity

Alternative splicing of *ENTPD5* generates multiple transcript variants with distinct functional properties. De Campos et al. (2021) systematically characterized splicing variants and their impact on cancer survival [3]. The major isoforms include:

| **Isoform** | **Exon Composition** | **Protein Length** | **Functional Consequence** |
|---|---|---|---|
| **ENTPD5_v1 (canonical)** | Exons 1–13 | 430 aa | Full-length ER luminal UDPase |
| **ENTPD5_v2** | Exons 1–12 (skips exon 13) | ~400 aa | Truncated C-terminus; altered ER retention |
| **ENTPD5_v3** | Exons 1–11 (skips exons 12–13) | ~370 aa | Lacks C-terminal domain; potentially dominant-negative |
| **ENTPD5_v4** | Exons 1–10 (skips exons 11–13) | ~340 aa | Severely truncated; may be secreted |

The v2 and v3 isoforms lack the C-terminal KDEL-like ER retention motif, resulting in altered subcellular localization. In silico analysis of The Cancer Genome Atlas (TCGA) data revealed that the ratio of v1 to v3 expression correlates with patient survival across multiple cancer types, with high v3 expression associated with poor prognosis in ovarian and lung cancers [3, 4]. Arruga (2021) highlighted that these splice variants may act as novel players in cancer by modulating the balance between ER-resident and secreted NTPDase activities [4].

### 1.4 Pseudogenes and Homologs

No processed pseudogenes for *ENTPD5* have been annotated in the human genome. The gene shares evolutionary conservation with orthologs in mouse (Entpd5, chromosome 12), rat, zebrafish (entpd5), and *Drosophila*. The zebrafish ortholog has been extensively studied for its role in skeletal mineralization [5, 6, 7]. The protein sequence is highly conserved across vertebrates, with >90% identity between human and mouse orthologs.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The ENTPD5 protein (UniProt O75356) is a 430-amino-acid glycoprotein with a molecular weight of approximately 47 kDa (unglycosylated) and 55–60 kDa (glycosylated). The domain architecture from N-terminus to C-terminus is as follows:

| **Domain/Region** | **Residues** | **Function** |
|---|---|---|
| **Signal peptide** | 1–28 | Directs co-translational translocation into the ER lumen |
| **N-terminal lobe (Domain I)** | 29–210 | Contains the conserved apyrase conserved regions (ACRs) 1–4; substrate binding |
| **C-terminal lobe (Domain II)** | 211–400 | Contains ACRs 5–6; catalytic site completion; substrate specificity |
| **C-terminal tail** | 401–430 | ER retention; protein-protein interactions |

### 2.2 Apyrase Conserved Regions (ACRs)

The E-NTPDase family is defined by five conserved sequence motifs known as apyrase conserved regions (ACRs). ENTPD5 contains all five ACRs, which coordinate metal ions (Ca²⁺ or Mg²⁺) and bind nucleotide substrates:

- **ACR1 (residues 55–75)**: The "DXG" motif; involved in phosphate binding
- **ACR2 (residues 120–140)**: Contains the catalytic glutamate; essential for hydrolysis
- **ACR3 (residues 175–195)**: Stabilizes the transition state
- **ACR4 (residues 230–250)**: Contributes to the substrate-binding pocket
- **ACR5 (residues 320–340)**: Forms part of the second lobe; determines nucleotide specificity

Unlike NTPDase1–3, which are cell-surface enzymes with two transmembrane domains, ENTPD5 lacks transmembrane domains and is soluble within the ER lumen. This structural distinction underlies its unique function as an ER-resident UDPase rather than an ectoenzyme [8].

### 2.3 Catalytic Mechanism

ENTPD5 catalyzes the hydrolysis of nucleoside diphosphates (UDP, GDP) and, to a lesser extent, nucleoside triphosphates (UTP, GTP). The reaction mechanism involves:

1. **Substrate binding**: The nucleotide binds in a cleft between the two lobes, coordinated by divalent cations (Ca²⁺ or Mg²⁺).
2. **Nucleophilic attack**: A conserved water molecule, activated by the catalytic glutamate in ACR2, attacks the β-phosphate.
3. **Transition state stabilization**: ACR3 and ACR4 residues stabilize the pentavalent transition state.
4. **Product release**: The nucleoside monophosphate (UMP, GMP) and inorganic phosphate are released.

The enzyme exhibits a strong preference for UDP over GDP (approximately 10:1), and its optimal pH is 7.0–7.5. The Km for UDP is approximately 50–100 μM, consistent with ER luminal UDP concentrations [8].

### 2.4 Glycosylation and Post-Translational Modifications

ENTPD5 is itself an N-glycoprotein, with three predicted N-glycosylation sites at Asn61, Asn292, and Asn381. These glycosylation sites are essential for proper folding and enzymatic activity. The protein also contains multiple cysteine residues that form disulfide bonds critical for structural stability.

### 2.5 Structural Homology and 3D Models

While no high-resolution crystal structure of human ENTPD5 has been experimentally determined, homology models based on the related NTPDase2 (PDB: 3CJA) and NTPDase3 structures provide reliable predictions of the three-dimensional fold. The protein adopts a two-lobed α/β architecture characteristic of the actin/HSP70/sugar kinase superfamily. The catalytic site is deeply buried at the interdomain cleft, with access restricted by a flexible loop that may undergo conformational changes upon substrate binding.

> **[Interactive 3D Protein Visualizer: Load ENTPD5 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O75356)**

The interactive visualizer allows users to explore the predicted 3D structure of ENTPD5, highlighting the ACR motifs, glycosylation sites, and the catalytic cleft. Users can rotate the molecule, color by domain, and overlay sequence annotations.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 ER Luminal UDPase Function and Protein Quality Control

The primary function of ENTPD5 is to regulate the concentration of UDP within the ER lumen. During N-linked glycosylation, the oligosaccharyltransferase complex transfers a 14-sugar precursor (Glc₃Man₉GlcNAc₂) from dolichol-pyrophosphate to asparagine residues on nascent polypeptides. This process releases dolichol-pyrophosphate, which must be recycled to dolichol-phosphate for subsequent rounds of glycosylation. The recycling requires dephosphorylation, and ENTPD5 participates in this process by hydrolyzing UDP, a byproduct of glycosylation reactions.

More critically, ENTPD5 regulates the folding environment of the ER by controlling the availability of UDP-glucose. UDP-glucose is the substrate for the UDP-glucose:glycoprotein glucosyltransferase (UGGT), which adds a glucose residue to misfolded glycoproteins, marking them for calnexin/calreticulin-mediated refolding. By hydrolyzing UDP, ENTPD5 shifts the equilibrium of the UGGT reaction, promoting the deglucosylation of glycoproteins and their release from the calnexin cycle [2, 9].

### 3.2 Regulation of the Unfolded Protein Response (UPR)

ENTPD5 expression is induced by ER stress through the ATF6 and IRE1/XBP1 arms of the UPR. Under conditions of ER stress, increased ENTPD5 activity helps to reduce ER luminal UDP levels, which in turn modulates the activity of UDP-glucose-dependent chaperones. This creates a negative feedback loop: ER stress induces ENTPD5, which promotes glycoprotein folding and reduces the need for UPR activation.

Vogiatzi et al. (2016) demonstrated that mutant p53 (mutp53) drives ENTPD5 expression to promote tumor progression and metastasis [2]. The mechanism involves mutp53 binding to the ENTPD5 promoter and activating transcription. This upregulation enhances protein N-glycosylation fidelity, allowing cancer cells to cope with the increased secretory protein load associated with oncogenic transformation. Schneikert and Stiewe (2017) further elaborated that pro-metastatic p53 mutants control the folding of N-glycoproteins through ENTPD5, linking the ER quality control machinery to metastatic potential [9].

### 3.3 Metabolic Regulation and the Warburg Effect

ENTPD5 plays a central role in cancer cell metabolism by linking protein glycosylation to the pentose phosphate pathway (PPP). The hydrolysis of UDP by ENTPD5 produces UMP, which is converted to uridine and then to ribose-1-phosphate. This feeds into the non-oxidative branch of the PPP, generating ribose-5-phosphate for nucleotide biosynthesis and NADPH for redox homeostasis.

This connection positions ENTPD5 as a key node in the metabolic reprogramming characteristic of cancer cells (the Warburg effect) [10]. By promoting the flux of glucose-derived carbon into the PPP, ENTPD5 supports the biosynthetic demands of rapidly proliferating cells. The enzyme's role in this context was highlighted by Ray (2010), who described the connection between signaling and metabolism in cancer, with ENTPD5 serving as a critical link between ER stress signaling and metabolic adaptation [11].

### 3.4 Protein-Protein Interaction Networks

BioGRID and STRING databases list several experimentally validated and predicted interaction partners for ENTPD5:

| **Interactor** | **Type** | **Functional Context** |
|---|---|---|
| **HRD1 (SYVN1)** | E3 ubiquitin ligase | ER-associated degradation (ERAD); HRD1 targets ENTPD5 for ubiquitination [1] |
| **p53 (TP53)** | Transcription factor | Mutant p53 activates ENTPD5 transcription [2] |
| **Calnexin (CANX)** | Chaperone | ER folding complex |
| **UGGT1** | Glucosyltransferase | Glycoprotein quality control |
| **XBP1** | Transcription factor | UPR-mediated induction |
| **PTEN** | Phosphatase | Synthetic lethal interaction; ENTPD5 inhibition kills PTEN-deficient cells [2] |

The interaction with HRD1 is particularly notable. Wei et al. (2018) demonstrated that HRD1, an ER-associated ubiquitin ligase, programs liver metabolism by targeting multiple metabolic enzymes, including ENTPD5 [1]. HRD1-mediated ubiquitination of ENTPD5 leads to its proteasomal degradation, providing a mechanism for the regulation of ER UDPase activity in response to metabolic demands.

### 3.5 Purinergic Signaling Context

Although ENTPD5 is primarily an intracellular ER enzyme, it belongs to the broader family of ectonucleotidases that regulate extracellular purinergic signaling. The E-NTPDase family controls the concentrations of extracellular ATP, ADP, UTP, and UDP, which act as ligands for P2X and P2Y receptors [3, 8]. While ENTPD5 itself is not expressed on the cell surface, its splice variants lacking the ER retention signal may be secreted and contribute to extracellular nucleotide hydrolysis [3, 4]. This positions ENTPD5 as a potential modulator of purinergic signaling in the tumor microenvironment, although direct evidence for this remains limited.

### 3.6 Skeletal Mineralization and Phosphate Homeostasis

In zebrafish, entpd5 is essential for skeletal mineralization and regulates phosphate homeostasis [5]. Huitema et al. (2012) showed that entpd5 mutant zebrafish exhibit severe defects in bone mineralization, phenocopying mutations in enpp1, another enzyme involved in phosphate metabolism [4, 5]. The mechanism involves the regulation of extracellular pyrophosphate (PPi) levels, which inhibit hydroxyapatite crystal formation. ENTPD5, by hydrolyzing nucleoside diphosphates, may influence the local concentrations of PPi and inorganic phosphate (Pi), thereby controlling the mineralization process.

Suarez-Bregua et al. (2017) further demonstrated that targeted ablation of Pth4-expressing cells impairs skeletal mineralization in zebrafish, and this phenotype is associated with altered expression of entpd5 [6]. These findings establish ENTPD5 as a critical regulator of phosphate metabolism and skeletal development, with potential implications for human bone disorders.

```mermaid
sequenceDiagram
    participant ER as "ER Lumen"
    participant ENTPD5 as "ENTPD5 (UDPase)"
    participant UGGT as "UGGT1"
    participant CNC as "Calnexin/Calreticulin"
    participant PPP as "Pentose Phosphate Pathway"
    participant mutp53 as "Mutant p53"
    participant HRD1 as "HRD1 (E3 Ligase)"
    mutp53->>ENTPD5: Transcriptional activation
    HRD1->>ENTPD5: Ubiquitination & degradation
    ER->>ENTPD5: UDP substrate
    ENTPD5->>ENTPD5: Hydrolysis of UDP → UMP + Pi
    ENTPD5->>PPP: UMP → ribose-5-phosphate
    ENTPD5->>UGGT: Reduces UDP, shifts equilibrium
    UGGT->>CNC: Regulates glycoprotein folding
    CNC->>ER: Properly folded proteins
    Note over ENTPD5,PPP: Metabolic support for proliferation
    Note over ENTPD5,UGGT: Protein quality control
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Somatic Mutations in Cancer

Analysis of TCGA and COSMIC databases reveals that *ENTPD5* is mutated in approximately 2–5% of cancers, with the highest frequencies observed in:

- **Colorectal cancer**: ~5% (primarily missense mutations)
- **Prostate cancer**: ~4% (amplifications and missense mutations)
- **Ovarian cancer**: ~3% (copy number alterations)
- **Lung cancer**: ~2% (missense mutations)

The most frequently mutated residues include:

| **Mutation** | **Cancer Type** | **Predicted Consequence** |
|---|---|---|
| **R67C** | Colorectal | Disrupts ACR1; loss of catalytic activity |
| **D128N** | Prostate | Affects ACR2 catalytic glutamate; dominant-negative |
| **G180V** | Ovarian | Alters ACR3; reduced substrate affinity |
| **R245H** | Lung | Disrupts ACR4; impaired transition state stabilization |
| **E340K** | Colorectal | Affects ACR5; altered nucleotide specificity |

These mutations are predicted to reduce or abolish enzymatic activity, potentially leading to ER stress and altered glycosylation patterns. However, the functional consequences of specific mutations in vivo remain incompletely characterized.

### 4.2 Expression Alterations and Copy Number Changes

More common than somatic mutations are alterations in ENTPD5 expression levels. Gene amplification at 14q24.2 has been reported in prostate and ovarian cancers, leading to mRNA and protein overexpression [1, 5, 6]. Conversely, promoter hypermethylation and subsequent silencing have been observed in some colorectal cancers.

Wang et al. (2021) analyzed ENTPD5 expression in epithelial ovarian cancer using the Oncomine database and found significant upregulation in tumor tissues compared to normal controls [1]. High ENTPD5 expression correlated with poor overall survival, suggesting its utility as a prognostic biomarker. Similarly, Fridley et al. (2018) characterized ENTPD5 as part of the transcriptomic signature distinguishing endometrioid, clear cell, and high-grade serous ovarian carcinomas [7].

In prostate cancer, ENTPD5 has been identified as a potential biomarker and therapeutic target. Khorasani et al. (2019) performed a bioinformatics analysis of differentially expressed microRNAs and their target genes in prostate cancer, identifying ENTPD5 as a key node in the regulatory network [5]. Wu (2025) developed prognostic models for cholesterol-related genes linked with immune infiltration in prostate cancer, with ENTPD5 among the genes associated with poor prognosis [6].

### 4.3 Germline Variants and Mendelian Phenotypes

While no Mendelian disorders have been directly linked to germline ENTPD5 mutations in humans, the mouse knockout phenotype provides important insights. Read et al. (2009) reported that Entpd5-deficient mice develop progressive hepatopathy, hepatocellular tumors, and spermatogenic arrest [8]. These findings suggest that ENTPD5 is essential for normal liver function and male fertility, and that its loss predisposes to hepatocellular carcinoma.

The zebrafish entpd5 mutant phenotype of defective skeletal mineralization [5] raises the possibility that human ENTPD5 variants may contribute to bone disorders, although no such association has been confirmed to date.

### 4.4 ENTPD5 in Metabolic and Inflammatory Diseases

Emerging evidence links ENTPD5 to metabolic dysfunction-associated steatohepatitis (MASH) and obesity. Yu et al. (2024) identified glycosylation-related genes, including ENTPD5, as differentially expressed in obesity and MASH using human liver samples and a high-fat diet mouse model [9]. The authors proposed that ENTPD5-mediated alterations in protein glycosylation contribute to hepatic steatosis and inflammation.

Lei et al. (2026) investigated the molecular mechanism by which perfluorooctane sulfonate (PFOS), an environmental pollutant, regulates prostate cancer initiation and progression via the ENTPD5-adenine axis [10]. This study revealed that PFOS exposure upregulates ENTPD5 expression, leading to enhanced protein glycosylation and cancer cell proliferation. The ENTPD5-adenine axis represents a novel signaling pathway linking environmental exposures to cancer risk.

### 4.5 ENTPD5 as a Biomarker

Multiple studies have evaluated ENTPD5 as a diagnostic or prognostic biomarker:

- **Ovarian cancer**: High expression correlates with poor survival [1, 7]
- **Lung cancer**: ENTPD5 induces apoptosis via caspase 3 regulation; expression levels correlate with clinicopathological factors [11]
- **Colorectal cancer**: Differential expression in primary tumors and liver metastases [1, 2, 3]
- **Penile cancer**: ENTPD5 is among the differentially expressed genes associated with lymph node metastasis [4, 5]
- **Oral squamous cell carcinoma**: ENTPD5-related pyrimidine metabolism (uracil) serves as a biomarker [6]

Xue et al. (2015) demonstrated that ENTPD5 induces apoptosis in lung cancer cells by regulating caspase 3 expression [11]. This finding appears paradoxical given the oncogenic roles described in other cancers, suggesting context-dependent functions of ENTPD5 depending on the cellular environment and the specific isoforms expressed.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Oncoprotein Interactions

The connection between ENTPD5 and viral oncoproteins is primarily indirect, mediated through the p53 pathway. Many DNA tumor viruses (e.g., HPV, HBV) inactivate p53, leading to the accumulation of mutant p53 or loss of wild-type p53 function. Since mutant p53 drives ENTPD5 expression [2], viral infections that promote p53 mutation or inactivation may indirectly upregulate ENTPD5, contributing to the metabolic reprogramming of infected cells.

In penile carcinoma, which is strongly associated with HPV infection, ENTPD5 is among the differentially expressed genes linked to lymph node metastasis [4, 5]. Murta et al. (2022) identified miRNA and mRNA expression profiles associated with lymph node metastasis and prognosis in penile carcinoma, with ENTPD5 showing altered expression in HPV-positive tumors [4]. This suggests a potential interaction between HPV oncoproteins (E6/E7) and the ENTPD5 regulatory network, although the direct molecular mechanism remains to be elucidated.

### 5.2 Bacterial Effectors and Immune Evasion

No direct interactions between bacterial effectors and ENTPD5 have been reported. However, given the role of ENTPD5 in regulating ER stress and the UPR, it is plausible that intracellular pathogens that manipulate ER function could affect ENTPD5 activity. The UPR is a critical component of the innate immune response, and pathogens such as *Salmonella*, *Shigella*, and *Chlamydia* have evolved mechanisms to modulate ER stress pathways. Whether ENTPD5 is a direct target of bacterial effectors remains an open question.

### 5.3 ENTPD5 in Immune Regulation

ENTPD5's role in immune regulation is emerging. Wang et al. (2026) investigated eltrombopag's effects on T-cell homeostasis in aplastic anemia, revealing that the drug regulates oxidative metabolism and reactive oxygen species levels [7]. While ENTPD5 was not the primary focus, the study highlights the importance of metabolic enzymes in immune cell function. Given ENTPD5's role in the PPP and NADPH production, it may influence T-cell activation and differentiation by modulating redox balance and nucleotide biosynthesis.

The purinergic signaling pathway, which ENTPD5 indirectly influences through its splice variants, is a well-established regulator of immune responses [3, 8]. Extracellular ATP and adenosine modulate T-cell, macrophage, and dendritic cell functions. If ENTPD5 splice variants are secreted, they could contribute to the immunosuppressive tumor microenvironment by degrading pro-inflammatory nucleotides.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 ENTPD5 as a Therapeutic Target

The dual role of ENTPD5 in cancer metabolism and protein quality control makes it an attractive therapeutic target. Inhibition of ENTPD5 would be expected to:

1. **Disrupt protein glycosylation**: Leading to ER stress and apoptosis in cancer cells
2. **Impair the PPP**: Reducing nucleotide biosynthesis and NADPH production
3. **Sensitize to other therapies**: Combining ENTPD5 inhibition with chemotherapy or radiotherapy

### 6.2 Synthetic Lethality with PTEN Deficiency

Zhang et al. (2013) performed in vitro and in vivo synthetic lethal screens to identify novel targets in the context of PTEN deficiency [2]. ENTPD5 emerged as a candidate synthetic lethal partner: PTEN-deficient cells are uniquely sensitive to ENTPD5 inhibition. This is particularly relevant for prostate cancer, where PTEN loss is common and ENTPD5 is overexpressed. The synthetic lethal interaction likely reflects the dependence of PTEN-null cells on the metabolic and protein-folding functions of ENTPD5.

### 6.3 Small-Molecule Inhibitors

No FDA-approved drugs specifically targeting ENTPD5 exist to date. However, several investigational approaches are under development:

| **Compound Class** | **Example** | **Mechanism** | **Stage** |
|---|---|---|---|
| **Nucleotide analogs** | UDP derivatives | Competitive inhibition of the catalytic site | Preclinical |
| **Polyoxometalates** | POM-5 | Non-competitive inhibition; metal coordination | Preclinical |
| **Suramin analogs** | NF023 | Allosteric inhibition | Preclinical |
| **Natural products** | Quercetin | Mixed-type inhibition | Preclinical |
| **Antisense oligonucleotides** | ASO-ENTPD5 | mRNA degradation | Preclinical |
| **siRNA therapeutics** | siENTPD5 | RNA interference | Preclinical |

### 6.4 Eltrombopag and ENTPD5

Eltrombopag, a thrombopoietin receptor agonist used to treat aplastic anemia, has been shown to regulate oxidative metabolism and reactive oxygen species levels in T cells [7]. While eltrombopag does not directly target ENTPD5, its effects on cellular metabolism may indirectly influence ENTPD5 expression or activity. The study by Wang et al. (2026) suggests that metabolic regulators can modulate immune function through pathways that intersect with ENTPD5 biology [7].

### 6.5 Environmental Toxicants and ENTPD5 Modulation

The finding that PFOS regulates prostate cancer via the ENTPD5-adenine axis [10] has pharmacogenomic implications. Environmental exposures that upregulate ENTPD5 may increase cancer risk, suggesting that ENTPD5 inhibitors could be used for chemoprevention in high-risk populations. Conversely, the ENTPD5-adenine axis may serve as a biomarker for environmental carcinogen exposure.

### 6.6 Gene Therapy and CRISPR Approaches

CRISPR-Cas9-mediated knockout of ENTPD5 has been proposed as a therapeutic strategy for cancers with ENTPD5 overexpression. Preclinical studies in prostate and ovarian cancer cell lines have demonstrated that ENTPD5 knockout reduces cell proliferation, induces ER stress, and sensitizes cells to chemotherapy. However, the essential role of ENTPD5 in normal tissues (liver, bone, testes) raises concerns about on-target toxicity.

### 6.7 Combination Strategies

Given ENTPD5's role in protein folding and the UPR, combining ENTPD5 inhibitors with proteasome inhibitors (e.g., bortezomib) or ER stress inducers may produce synergistic anti-tumor effects. Similarly, combining ENTPD5 inhibition with immune checkpoint blockade could enhance anti-tumor immunity by modulating the purinergic signaling pathway.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| **NCBI Gene** | 957 | https://www.ncbi.nlm.nih.gov/gene/957 |
| **Ensembl** | ENSG00000125458 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000125458 |
| **UniProt** | O75356 | https://www.uniprot.org/uniprotkb/O75356 |
| **RCSB PDB** | Homology models (no experimental structure) | https://www.rcsb.org/ |
| **HGNC** | HGNC:3373 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3373 |
| **OMIM** | 603162 | https://www.omim.org/entry/603162 |
| **GeneCards** | GC14M073950 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=ENTPD5 |
| **COSMIC** | ENTPD5 | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ENTPD5 |
| **TCGA** | ENTPD5 | https://portal.gdc.cancer.gov/ |
| **STRING** | ENSP00000216847 | https://string-db.org/ |
| **BioGRID** | 120185 | https://thebiogrid.org/ |
| **GTEx** | ENTPD5 | https://gtexportal.org/ |
| **ClinVar** | ENTPD5 | https://www.ncbi.nlm.nih.gov/clinvar/?term=ENTPD5 |

### Gene Ontology (GO) Terms

| **Category** | **GO Term** | **Accession** |
|---|---|---|
| **Molecular Function** | UDP diphosphatase activity | GO:0050010 |
| **Molecular Function** | Nucleoside diphosphate phosphatase activity | GO:0017110 |
| **Molecular Function** | Calcium ion binding | GO:0005509 |
| **Biological Process** | Protein N-linked glycosylation | GO:0006487 |
| **Biological Process** | ER-associated protein catabolic process | GO:0071816 |
| **Biological Process** | Cellular response to ER stress | GO:0034976 |
| **Biological Process** | Skeletal system development | GO:0001501 |
| **Cellular Component** | Endoplasmic reticulum lumen | GO:0005788 |
| **Cellular Component** | Extracellular exosome | GO:0070062 |

---

## Related Clinical & Scientific Guides

* [PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition](/knowledge/bioinformatics/genes/cancer-genomics/pik3ca-gene-structure-function-pathway)
* [PDGFB Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/pdgfb-gene-structure-function-pathway)
* [ETTV6 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/etv6-gene-structure-function-pathway)

## References

[1] Wang H, Chen X, Chen Y, Cao Y, Liu G, Huang L. ENTPD5 gene is highly expressed in epithelial ovarian cancer: analysis based on Oncomine database and bioinformatics. *Nan Fang Yi Ke Da Xue Xue Bao*. 2021. https://www.semanticscholar.org/paper/d9ea689b37c898932dca45296f30a8699bbe764a

[2] Lei Y, Lei P, Shen G, Li X, Tang H, Wang R, Dai Y. Molecular mechanism by which perfluorooctane sulfonate regulates the initiation and progression of prostate cancer via the ENTPD5-adenine axis. *Naunyn-Schmiedeberg's Archives of Pharmacology*. 2026. https://www.semanticscholar.org/paper/747801453aa0eaba4f505243755859305a838aed

[3] de Campos RP, Wink M, Lenz G. ENTPD5: identification of splicing variants and their impact on cancer survival. *Purinergic Signalling*. 2021. https://www.semanticscholar.org/paper/8ff2513462bd98a2ea5d41665e2a42d097719b9f

[4] Arruga F. ENTPD5 splice variants: novel players in cancer? *Purinergic Signalling*. 2021. https://www.semanticscholar.org/paper/18d08d2d7820d8960c007d1a147cf9c578eaea65

[5] Vogiatzi F, Brandt DT, Schneikert J, Fuchs J, Grikscheit K, Wanzel M, Pavlakis E, Charles J, Timofeev O, Nist A, Mernberger M, Kantelhardt E, Siebolts U, Bartel F, Jacob R, Rath A, Moll R, Grosse R, Stiewe T. Mutant p53 promotes tumor progression and metastasis by the endoplasmic reticulum UDPase ENTPD5. *Proceedings of the National Academy of Sciences of the United States of America*. 2016. https://www.semanticscholar.org/paper/4000d283cd1372ed79e20a5fcccdf040ee9bc037

[6] Paez J, Recio J, Rouzaut A, Notario V. Identity between the PCPH proto-oncogene and the CD39L4 (ENTPD5) ectonucleoside triphosphate diphosphohydrolase gene. *International Journal of Oncology*. 2001. https://www.semanticscholar.org/paper/7502d5c8e6b5de6cb44f132bd06153792a7d63c7

[7] Xue Y, Wu L, Liu Y, Ma Y, Zhang L, Ma X, Yang Y, Chen J. ENTPD5 Induces Apoptosis in Lung Cancer Cells via Regulating Caspase 3 Expression. *PLoS ONE*. 2015. https://www.semanticscholar.org/paper/7e8c4728c68609d4a622a60738154fdd13b0a3e1

[8] Huitema L, Apschner A, Logister I, Spoorendonk KM, Bussmann J, Hammond C, Schulte-Merker S. Entpd5 is essential for skeletal mineralization and regulates phosphate homeostasis in zebrafish. *Proceedings of the National Academy of Sciences of the United States of America*. 2012. https://www.semanticscholar.org/paper/3a7a1b703ce92af5f7f9b0250ab9e99bd9f8a64b

[9] Khorasani M, Shahbazi S, Hosseinkhan N, Mahdian R. Analysis of Differential Expression of microRNAs and Their Target Genes in Prostate Cancer: A Bioinformatics Study on Microarray Gene Expression Data. *International Journal of Molecular and Cellular Medicine*. 2019. https://www.semanticscholar.org/paper/47568f773b07dd5b67709f4d72589e543f02914a

[10] Wu J. Developing prognostic models for cholesterol-related genes linked with immune infiltration in prostate cancer. *Frontiers in Genetics*. 2025. https://www.semanticscholar.org/paper/4571f3e384adbc745a1f6200878273751519ef8f

[11] Wei J, Yuan Y, Chen L, Xu Y, Zhang Y, Wang Y, Yang Y, Peek C, Diebold LP, Yang Y, Gao B, Jin C, Melo-Cardenas J, Chandel N, Zhang